Skip to main content

Table 4 Post-treatment changes in CRP, ESR, and Igs

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

 

Post-treatment change from baseline (mean ± standard deviation)

Parameters

6 weeks

10 weeks

18 weeks

32 weeks

 

n = 13

n = 13

n = 12

n = 10

CRP

0.42 ± 1.39

-0.02 ± 0.33

0.19 ± 0.60

0.03 ± 0.22

ESR

1.3 ± 15.0

1.5 ± 11.0

-0.9 ± 7.7

-0.3 ± 11.6

 

n = 15

n = 13

n = 13

n = 9

IgG

29.7 ± 249.6

-31 ± 379.6

7.1 ± 313.5

-120.8 ± 363.3

IgA

1.1 ± 24.4

7.8 ± 46.9

-1.2 ± 59

-3.8 ± 62.4

IgM

-14.9 ± 25.3

-9.6 ± 28.3

-15.0 ± 32.8

-2.3 ± 34.8

  1. None of the changes from baseline in the above parameters was statistically significant. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, immunoglobulin.